We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » India Trade Group: Bolster Components Sector to Enhance Medtech

India Trade Group: Bolster Components Sector to Enhance Medtech

August 14, 2015

A trade group is calling on India’s Department of Pharmaceuticals to promote incentives for the country’s components industry, saying doing so will help to fuel domestic manufacturing of medical devices.

Boosting micro, small and medium enterprises in the components sector would encourage Prime Minister Narendra Modi’s “Make in India” program, the Confederation of Indian Industry says in an Aug. 4 document. The program aims to transform India into a global manufacturing hub for a range of industries.

“CII has emphasized the importance of recognizing the fact that the manufacturing business case in India is quite challenging,” the trade group says.

“While the labor costs are lower in the country, the capital investment and productivity of the labor are critical limiting factors to the manufacturing business case. Combined with approval delays, this makes the manufacturing environment quite challenging for entrepreneurs,” it adds.

To help overcome these challenges, the group recommends creating medical technology manufacturing hubs throughout the country.

The government could offer subsidized land prices to set up these hubs, as well as develop joint ventures, licensing agreements and public-private partnerships to enhance the manufacturing ecosystem.

CII singles out Singapore and Ireland as examples of countries where hubs have helped to foster innovation. Singapore’s medical technology industry nearly tripled its manufacturing output from about US $1.1 billion in 2000 to about $3.1 billion in 2011.

Meanwhile, Ireland has seen tremendous success in its devices sector, which enjoys annual sales of more than $6.6 billion.

The recommendation echoes a call earlier this year by the public-private Task Force on the Medical Devices Sector in India for device hubs with common medical device testing facilities that would be funded at least partially by industry (IDDM, April 17).

The group also proposes low-cost capital through favorable loans and tax incentives to spur investment and lure manufacturers to India. These manufacturers would improve the components ecosystem, giving local companies access to their products.

CII also argues that the regulatory bar is set too high for devicemakers, with a Byzantine process requiring approvals from a range of agencies. Simplifying the process would help bolster the industry.

The group says that incentivizing components makers should be a higher priority than implementing the preferential market access policy for medical devices, which gives preferential treatment to domestic goods to encourage Indian manufacturing.

Currently, a PMA policy is in place for procurement of electronics and information and communication technologies by government and state-owned enterprises. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing